Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Cytosorbents Corporation is a medical technology company focused on developing and commercializing blood purification therapies for the treatment of life-threatening conditions in critical care and cardiac surgery. The company operates within the medical devices and critical care therapeutics industries, with its core technology designed to remove harmful substances such as inflammatory cytokines, toxins, and other pathogenic mediators directly from the bloodstream.
The company’s primary revenue driver is its flagship product, CytoSorb, an extracorporeal hemoadsorption device used primarily in intensive care units and during complex cardiac surgeries. Cytosorbents serves hospitals and healthcare providers treating patients with sepsis, severe inflammation, trauma, liver dysfunction, and complications following cardiac surgery. Founded in 2006, Cytosorbents evolved from a research-stage enterprise into a commercial-stage medical device company, achieving regulatory approvals outside the United States earlier in its history and progressively expanding its clinical evidence base and commercial reach.
Business Operations
Cytosorbents generates revenue through the sale of its blood purification devices and related disposables, with operations organized around its core hemoadsorption technology platform. The company’s commercial portfolio includes CytoSorb, ECMO CytoSorb, and PuriFi, which are integrated into existing extracorporeal circulation systems such as dialysis machines, heart-lung machines, and ECMO circuits. Sales are driven primarily by recurring disposable usage rather than capital equipment sales.
Operations are international in scope, with a significant portion of revenue generated outside the United States, particularly in Europe. Cytosorbents conducts research and development internally and through clinical collaborations, and it maintains wholly owned subsidiaries including CytoSorbents Europe GmbH and CytoSorbents USA, Inc. The company also engages in distribution partnerships in select international markets to expand adoption while maintaining direct sales capabilities in core regions.
Strategic Position & Investments
Cytosorbents’ strategic direction centers on expanding the clinical indications, geographic adoption, and evidence base for its hemoadsorption technologies. Growth initiatives include increasing penetration in cardiac surgery, sepsis, and intensive care, as well as pursuing regulatory approvals for broader use cases. The company has invested significantly in clinical trials and post-market studies to support regulatory submissions, including efforts toward potential U.S. regulatory clearance for expanded indications.
The company has also pursued selective acquisitions and technology investments aligned with blood purification and organ support therapies. Notable investments include the acquisition of PuriFi Manufacturing, which enhanced internal manufacturing capabilities and supply chain control. Cytosorbents continues to explore emerging applications in immune modulation and organ protection, positioning its platform as a complementary therapy to existing extracorporeal support technologies.
Geographic Footprint
Cytosorbents is headquartered in North America, with its corporate headquarters located in the United States. The company maintains a strong operational and commercial presence in Europe, which represents its largest revenue-generating region, supported by regulatory approvals and established clinical adoption across multiple countries.
Beyond Europe and North America, Cytosorbents has market exposure in parts of Asia-Pacific, Latin America, and the Middle East through distributor networks and regional partnerships. Its products have been used in hospitals across more than 60 countries, reflecting a broad international footprint despite a relatively concentrated commercial infrastructure.
Leadership & Governance
Cytosorbents was founded by Phillip Chan, who continues to play a central role in shaping the company’s strategy and technology development. The leadership team emphasizes a clinically driven innovation philosophy, focusing on evidence-based expansion, disciplined capital allocation, and long-term value creation through differentiated medical technology.
Key executives include:
- Phillip Chan � Chief Executive Officer
- Robert Kowalski � Chief Financial Officer
- Vincent Forlenza � Chairman of the Board
- Dr. Michael Rosin � Chief Medical Officer
- Eric Peters � Chief Operating Officer
The company is governed by a board of directors with experience in medical devices, healthcare operations, and public company oversight, supporting regulatory compliance and strategic execution.